Myriad Genetics Inc (MYGN)

17.78 -0.43  -2.36% NASDAQ Nov 27, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/05/2021 Earnings Myriad Genetics Inc Second Quarter Earnings for 2021 Release
02/05/2021 16:30 EST Misc Myriad Genetics Inc Second Quarter Earnings Conference Call for 2021
11/09/2020 Earnings Myriad Genetics Inc First Quarter Earnings Result for 2021
11/09/2020 17:00 EST Misc Myriad Genetics Inc First Quarter Earnings Conference Call for 2021
08/13/2020 16:30 EDT Misc Myriad Genetics Inc Fourth Quarter Earnings Conference Call for 2020
08/13/2020 Earnings Myriad Genetics Inc Fourth Quarter Earnings Result for 2020
08/13/2020 Misc Myriad Genetics Inc Annual Report for 2020
05/05/2020 16:30 EDT Misc Myriad Genetics Inc Third Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Myriad Genetics Inc Third Quarter Earnings Result for 2020
02/06/2020 16:30 EST Misc Myriad Genetics Inc Second Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.myriad.com
  • Investor Relations URL: https://myriad.com/news-center/investor-information/
  • HQ State/Province: Utah
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Feb. 05, 2021
  • Last Earnings Release: Nov. 09, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual’s risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Top Fund Holders

Symbol Name Weighting
F000013C68 FT Biotechnology 44 CA 2.21%
F000011O5S FT Biotechnology 43 F RE 1.97%
PSCH Invesco S&P SmallCap Health Care ETF 1.42%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.